Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.38 |
| ▸ | CMA1 | P23946 | 3/20 | 0.37 |
| ▸ | F10 | P00742 | 7/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672446 | 0.82 | PER2 (0.36) | LRRK2MAP4K1F10PIK3CD | |
| SCHEMBL21805487 | 0.81 | PIK3CD (0.40) | MAP4K1F10PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21805800 | 0.80 | PIK3CD (0.38) | MAP4K1F10PIK3CDPIK3CAPIK3CB | |
| SCHEMBL671134 | 0.78 | LRRK2 (0.50) | LRRK2PIK3CBPRKDCAKT1 | |
| SCHEMBL670523 | 0.74 | MAP4K1 (0.36) | LRRK2MAP4K1F10PIK3CD | |
| SCHEMBL10203358 | 0.73 | ADORA2A (0.38) | MAP4K1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29842516 | 0.73 | F10 (0.43) | F10 | |
| SCHEMBL28809954 | 0.72 | PKM (0.45) | MAP4K1F10 | |
| SCHEMBL21921487 | 0.72 | JAK2 (0.39) | MAP4K1CMA1F10PIK3CDPIK3CA | |
| SCHEMBL30087730 | 0.72 | JAK2 (0.39) | MAP4K1CMA1F10PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | LRRK2 2904/4885MAP4K1 246/4885CMA1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.